Ann: Q2 2024 update, page-40

You may very well be right - but then again you may not.

Yours is a very narrow purely numbers-based view and are entitled to it.

But not all drugs are the same. Daybue's situation may not be limited to current performance alone. It is treating a very complex neuro condition, with much anecdotal significant success and development of strategies to overcome tolerance issues. It's value may not crystalize in the marketplace for some time to come yet. To combat that as an investment we have 2591 following hot on its heels.

I for one believe it is way too premature (and disrespectful to many affected people) to categorize it as a "dud".

How about we compare notes in a year or so. I can't wait for that year to pass in respect of Daybue and especially 2591.